Učitavanje...
The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5
INTRODUCTION: Lenalidomide is an active agent that was approved for use in the EU in 2015 as a first-line therapy for previously untreated, non-transplant eligible multiple myeloma patients. Our objective was to assess the cost impact of lenalidomide when selected as a first-line treatment for trans...
Spremljeno u:
| Izdano u: | Oncol Ther |
|---|---|
| Glavni autori: | , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Springer Healthcare
2017
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5488111/ https://ncbi.nlm.nih.gov/pubmed/28680953 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40487-016-0037-8 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|